Biodrugs

Papers
(The TQCC of Biodrugs is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond371
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis337
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy140
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor116
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis101
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery100
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome81
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making78
Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials68
Why Product Drift Is Not an Issue for Biosimilars/Biologics: Start the Same, Stay the Same63
Acknowledgement to Referees56
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials47
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart44
CAR-T Cells and the Kidney: Insights from the WHO Safety Database43
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202240
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?39
Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France38
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells38
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study36
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis36
Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities35
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase34
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review34
Progress and Challenges in the Treatment of Fabry Disease34
Malaria Vaccines: Progress to Date32
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer31
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?30
Interleukin-23 Inhibitors in Inflammatory Bowel Disease29
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects29
Acknowledgement to Referees28
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?28
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series28
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?27
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options27
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network27
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight25
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment25
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review25
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study24
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics22
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects21
Recombinant Protein Drugs: A 2025 Update21
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa21
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Stu20
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis20
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy20
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review20
The Use of Biologics for Thyroid Eye Disease19
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab19
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression18
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials18
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study17
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine17
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database17
Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection16
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs16
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies16
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases16
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria16
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease15
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context15
Patients’ Perceptions of Biosimilars: A Systematic Review14
Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria14
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing14
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance14
0.084256887435913